SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-16-007893
Filing Date
2016-08-11
Accepted
2016-08-11 08:48:47
Documents
60
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20160630x10q.htm 10-Q 1284690
2 EX-31.1 acrs-20160630ex311406163.htm EX-31.1 14057
3 EX-31.2 acrs-20160630ex312f847aa.htm EX-31.2 14043
4 EX-32.1 acrs-20160630ex3214f0b62.htm EX-32.1 10511
  Complete submission text file 0001558370-16-007893.txt   5667230

Data Files

Seq Description Document Type Size
5 EX-101.INS acrs-20160630.xml EX-101.INS 1361737
6 EX-101.SCH acrs-20160630.xsd EX-101.SCH 34021
7 EX-101.CAL acrs-20160630_cal.xml EX-101.CAL 40360
8 EX-101.DEF acrs-20160630_def.xml EX-101.DEF 132186
9 EX-101.LAB acrs-20160630_lab.xml EX-101.LAB 374222
10 EX-101.PRE acrs-20160630_pre.xml EX-101.PRE 265837
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 161823123
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences